All In Biotech

Drug Trial Radar · NCT06932146

A Phase 2a Study of LLX-424 in Patients With a History of Kidney Stones

A Phase 2a Randomized, Double-blind, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamic (PD) Effects of LLX-424 in Patients With a History of Kidney Stones

Last checked: Nov 19, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51

Actual

Start

Mar 23, 2025

Primary completion

Sep 30, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Lilac Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Apr 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2a study of glycolate oxidase inhibitor LLX-424 in patients with a history of kidney stones. Eligible subjects with a history of kidney stones will be randomized to receive study drug (LLX-424 or placebo) for 8 weeks.

Conditions

  • Kidney Stones

Interventions

  • LLX-424Drug

    Tablets for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (TEAEs)Time frame: From the first dose and for up to 9 weeks
  2. Percentage of subjects with study drug-related severe laboratory-based AEsTime frame: From the first dose and for up to 9 weeks
  3. QT interval on ECGTime frame: From the first dose and for up to 9 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Research Site #2

    Saint Paul, Minnesota

  • Clinical Research Site #3

    Springfield, Missouri

  • Clinical Research Site #1

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.